OCTALFA

Sirius NeoSight is a biotechnology and pharmaceutical company focused on the early detection and treatment of subclinical neo-cancers. The company has developed innovative healthcare technology software that measures the fluidity of membranes specifically within the field of oncology. This patented technology is designed to enhance the detection and purification of Circulating Tumor Cells, contributing to advancements in personalized medicine. By addressing these critical aspects of cancer treatment, Sirius NeoSight aims to improve outcomes for patients through early intervention and tailored therapeutic approaches.

ORPHELIA Pharma SA is a French pharmaceutical company focused on the development and marketing of pediatric formulations targeting epilepsy, neurodegenerative disorders, and metabolic diseases. Founded in 2007 and headquartered in Paris, ORPHELIA Pharma aims to enhance the safety and efficacy of essential medicines for children through innovative formulations. The company's pipeline includes several key products: ORP-001, a reformulation of the antiepileptic drug vigabatrin; ORP-002, designed for Rett syndrome; ORP-003, another reformulation of an existing antiepileptic drug; and ORP-006, targeting a specific orphan form of neonatal epileptic encephalopathy. ORPHELIA Pharma is dedicated to improving the health and well-being of severely disabled children by developing optimized formulations for pediatric populations and seeking approvals for existing drugs in new pediatric orphan indications.

Mathym is a biomedical company specializing in the development and supply of colloidal nanomaterials primarily for dental applications. The company focuses on creating nano-dispersions that are integral to various industries, including dental, fine ceramics, photonics, displays, biomedical, and semiconductor manufacturing. These nano-dispersions enhance critical properties in medical devices by ensuring a steady and homogeneous dispersion of nanoparticles in liquids, facilitating improved research and development in these fields.

ORPHELIA Pharma SA is a French pharmaceutical company focused on the development and marketing of pediatric formulations targeting epilepsy, neurodegenerative disorders, and metabolic diseases. Founded in 2007 and headquartered in Paris, ORPHELIA Pharma aims to enhance the safety and efficacy of essential medicines for children through innovative formulations. The company's pipeline includes several key products: ORP-001, a reformulation of the antiepileptic drug vigabatrin; ORP-002, designed for Rett syndrome; ORP-003, another reformulation of an existing antiepileptic drug; and ORP-006, targeting a specific orphan form of neonatal epileptic encephalopathy. ORPHELIA Pharma is dedicated to improving the health and well-being of severely disabled children by developing optimized formulations for pediatric populations and seeking approvals for existing drugs in new pediatric orphan indications.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Nightswapping is a peer-to-peer accommodation exchange platform that connects a community of over 150,000 members who swap nights to travel and stay for free in each other's homes. By eliminating financial transactions, the platform fosters authentic experiences for both hosts and travelers while avoiding legal complications. Members can either exchange their nights for free stays in over 160 countries or convert their nights into real money if desired. Additionally, for those uncertain about their travel destinations, the platform offers suggestions for unexpected and exciting places to visit, enhancing the overall travel experience.

Mathym is a biomedical company specializing in the development and supply of colloidal nanomaterials primarily for dental applications. The company focuses on creating nano-dispersions that are integral to various industries, including dental, fine ceramics, photonics, displays, biomedical, and semiconductor manufacturing. These nano-dispersions enhance critical properties in medical devices by ensuring a steady and homogeneous dispersion of nanoparticles in liquids, facilitating improved research and development in these fields.

e(ye)BRAIN SA is a medical company based in Paris, France, that specializes in the development and manufacturing of eye trackers aimed at diagnosing neurological and psychiatric diseases. Founded in 2008, the company offers two primary products, EyeBrain T1 and EyeBrain T2. The EyeBrain T1 device records eye movements, while the EyeBrain T2 captures both eye and head movements using advanced algorithms. The data collected from these devices is analyzed through the MeyeEval software, which aids in clinical assessments. In addition to its core products, e(ye)BRAIN provides clinical research tools and offers advisory and support services, enhancing the functional exploration of the brain in both healthy and diseased states.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Laboratories JUVISE Pharmaceuticals is a multinational pharmaceutical company that specialises in acquiring, manufacturing and marketing treatments offering great therapeutic potential for patients around the world. Following the sale of Lynapharm laboratories to the Italian pharmaceutical group Sigma-Tau in 2008, Mr Mascha established JUVISE Pharmaceuticals company as an international pharmaceutical subsidiary of the JUVISE group. JUVISE Pharmaceuticals is a pharmaceutical company accredited by the ANSM, French National Agency for the Safety of Medicines and Health Products. The company specialises in manufacturing and marketing pharmaceutical products to treat cardiologic, psychiatric, rheumatic and respiratory/ENT conditions and also fertility/sexual matters. JUVISE Pharmaceuticals currently markets 8 speciality pharmaceutical products: Esidrex®, Sintrom®, Digoxin®, Entumin®, Insidon®, Lumirelax®, Calmixène®, Extovyl®. It also markets two food supplements: Proxeed®Plus and Proxeed®Women. These are sold in a total of 57 countries.

Graftys is an early-stage company based in Aix-en-Provence, France, specializing in advanced bone biologics. The company develops synthetic bone biomaterials specifically designed for reconstructive orthopedic surgery. Graftys offers a range of innovative and fully injectable calcium phosphate bone graft substitutes that are tailored for various clinical applications. By focusing on safety and quality, Graftys aims to provide effective solutions for patients undergoing bone reconstructive and trauma surgery.

Orega Biotech is a biotech company based in Écully, France, that focuses on developing immunotherapeutics for cancer treatment. Founded in 2010, the company specializes in the creation of monoclonal antibodies aimed at enhancing cancer immunotherapy. Orega Biotech's research emphasizes the tumor microenvironment and includes a target discovery program that seeks to identify and validate novel cancer targets relevant to clinical applications. By modulating the activities of regulatory T cells and improving therapeutic strategies, Orega Biotech aims to enhance patient response rates and overall survival in cancer treatments. The company is supported by INSERM-Transfert and OCTALFA, benefiting from a synergy of scientific and business expertise among its founders.

Docea Power SAS specializes in developing and marketing software solutions for power and thermal analysis at the architectural level of electronic systems. Its primary product, Aceplorer, facilitates the modeling, exploration, and optimization of power and thermal behavior across various electronic architectures, accommodating a range of model complexities and heterogeneous systems that include digital, analog, and mixed signal components. Additionally, Docea Power offers AceThermalModeler, which generates compact thermal models for system on chips, 3D integrated circuits, systems in package, or complete boards. The company also provides training and consultancy services to support its clients. Its software is utilized by original equipment manufacturers, system in package and system on chip manufacturers, as well as intellectual property and integrated circuit providers across diverse industries, including wireless, automotive, consumer electronics, aerospace, computing, and medical sectors. Founded in 2006 and headquartered in Moirans, France, Docea Power operates as a subsidiary of Intel Corporation.

Glycode SAS, a biotechnology company, operates in the field of protein glycosylation in France. It provides and licenses GlycodExpress, a yeast based technological platform for the production of recombinant therapeutic glycoproteins for therapeutic purposes, such as antibodies, EPOs, and growth factors, as well as allows humanization of N-glycosylation in Saccharomyces cerevisiae. The company also offers on-demand production and purification services, from the conception and synthesis of optimized expression vectors for protein expression in glycoengineered yeasts to the early steps of production process. Glycode SAS serves biotechnology and pharmaceutical companies. The company was founded in 2004 and is based in Uzerche, France.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Antagene is a French biotechnology company headquartered in Limonest, France, specializing in veterinary genetic testing for animals, particularly dogs and cats. The company develops and sells DNA tests that identify genetic diseases, such as night blindness and retinal atrophy, thereby promoting animal health and welfare. Antagene's offerings enable breeders to select healthy breeding animals and reduce the risk of passing on serious genetic disorders to offspring. By focusing on early detection and genetic profiling, Antagene aims to improve traceability and management within breeding practices, ultimately contributing to the prevention of genetic diseases in companion animals. As of 2016, Antagene operates as a subsidiary of CERBA VET, enhancing its capabilities in veterinary diagnostics.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.